ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,740.70
-0.08%
Dow Jones
42,362.29
0.44%
US Dollar vs MXN
19.71582
0.47%
Brent Oil
71.535
0.82%
Bitcoin
65,970.01
1.21%
Registration Strip Icon for monitor Monitoree múltiples cotizaciones en tiempo real de los principales intercambios, como la Bolsa de Valores de Londres, NASDAQ, NYSE, AMEX, Bovespa y más.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Reino Unido
  5. LSE
  6. Hikma Pharmaceuticals Plc (HIK)

  7. Hikma Pharmaceuticals Plc (HIK) Noticias

HIK

Hikma Pharmaceuticals (HIK)

Hikma Pharmaceuticals Plc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:LSE:HIK
FechaHoraFuenteTítuloSímboloCompañía
24/09/202404:09RNS Regulatory NewsHikma Pharmaceuticals Plc Director/PDMR ShareholdingLSE:HIKHikma Pharmaceuticals Plc
10/09/202403:09Alliance NewsAlliance NewsHikma Pharmaceuticals completes acquisition of Xellia's FDF businessLSE:HIKHikma Pharmaceuticals Plc
10/09/202401:00RNS Regulatory NewsHikma Pharmaceuticals Plc Hikma completes Xellia acquisitionLSE:HIKHikma Pharmaceuticals Plc
03/09/202406:46Alliance NewsAlliance NewsIN THE KNOW: Berenberg sees "standout" year at Hikma's Injectibles armLSE:HIKHikma Pharmaceuticals Plc
20/08/202411:15PR Newswire (US)Hikma Pharmaceuticals participates in naloxone training event with U.S. Congressman Buddy Carter ahead of National Fentanyl Awareness and Prevention DayLSE:HIKHikma Pharmaceuticals Plc
15/08/202414:18PR Newswire (US)KLOXXADO® 8mg Naloxone Nasal Spray Shelf-Life Extended from 24 months to 36 monthsLSE:HIKHikma Pharmaceuticals Plc
13/08/202404:16Alliance NewsAlliance NewsIN BRIEF: Hikma executive Bassam Kanaan sells 45,000 sharesLSE:HIKHikma Pharmaceuticals Plc
08/08/202405:33Alliance NewsAlliance NewsHikma Pharmaceuticals raises guidance as first-half profit jumps 43%LSE:HIKHikma Pharmaceuticals Plc
08/08/202401:00RNS Regulatory NewsHikma Pharmaceuticals Plc Half-year ReportLSE:HIKHikma Pharmaceuticals Plc
29/07/202410:08RNS Regulatory NewsHikma Pharmaceuticals Plc Director DeclarationLSE:HIKHikma Pharmaceuticals Plc
15/07/202401:00RNS Regulatory NewsHikma Pharmaceuticals Plc Notice of ResultsLSE:HIKHikma Pharmaceuticals Plc
01/07/202408:47RNS Regulatory NewsHikma Pharmaceuticals Plc Total Voting RightsLSE:HIKHikma Pharmaceuticals Plc
17/06/202403:14Alliance NewsAlliance NewsHikma adds scale to US injectables business with Xellia acquisitionLSE:HIKHikma Pharmaceuticals Plc
17/06/202401:00RNS Regulatory NewsHikma Pharmaceuticals Plc Hikma acquires Xellia’s assetsLSE:HIKHikma Pharmaceuticals Plc
11/06/202407:05Alliance NewsAlliance NewsIN THE KNOW: Citi lifts Hikma price target amid positive industry dataLSE:HIKHikma Pharmaceuticals Plc
25/04/202408:28RNS Regulatory NewsHikma Pharmaceuticals Plc Result of AGMLSE:HIKHikma Pharmaceuticals Plc
25/04/202404:15Alliance NewsAlliance NewsHikma Pharmaceuticals backs outlook after making strong start to 2024LSE:HIKHikma Pharmaceuticals Plc
25/04/202401:00RNS Regulatory NewsHikma Pharmaceuticals Plc Trading StatementLSE:HIKHikma Pharmaceuticals Plc
15/04/202410:43RNS Regulatory NewsHikma Pharmaceuticals Plc Hikma appoints new President of Generics businessLSE:HIKHikma Pharmaceuticals Plc
02/04/202403:50RNS Regulatory NewsHikma Pharmaceuticals Plc Block listing Interim ReviewLSE:HIKHikma Pharmaceuticals Plc
22/03/202404:21RNS Regulatory NewsHikma Pharmaceuticals Plc Annual Financial Report and Notice of AGMLSE:HIKHikma Pharmaceuticals Plc
22/02/202403:42Alliance NewsAlliance NewsTOP NEWS: Hikma boosts dividend after year of "significant progress"LSE:HIKHikma Pharmaceuticals Plc
22/02/202401:09Alliance NewsAlliance News*Hikma Pharmaceuticals says core operating profit to be in range of USD660m to USD700mLSE:HIKHikma Pharmaceuticals Plc
22/02/202401:08Alliance NewsAlliance News*Hikma Pharmaceuticals expect revenue to grow in the range of 4% to 6%LSE:HIKHikma Pharmaceuticals Plc
22/02/202401:08Alliance NewsAlliance News*Hikma Pharmaceuticals confident that strategy will continue to deliver growth in 2024LSE:HIKHikma Pharmaceuticals Plc
22/02/202401:07Alliance NewsAlliance News*Hikma Pharmaceuticals declares FY dividend of 73 US cents per share vs 56 cents YoYLSE:HIKHikma Pharmaceuticals Plc
22/02/202401:06Alliance NewsAlliance News*Hikma Pharmaceuticals 2023 pretax profit USD520m vs USD233m YoYLSE:HIKHikma Pharmaceuticals Plc
22/02/202401:06Alliance NewsAlliance News*REPEAT: Hikma Pharmaceuticals 2023 revenue USD2.88b vs USD2.52b YoYLSE:HIKHikma Pharmaceuticals Plc
22/02/202401:05Alliance NewsAlliance News*Hikma Pharmaceuticals 2023 USD2.88b vs USD2.52b YoYLSE:HIKHikma Pharmaceuticals Plc
22/02/202401:00RNS Regulatory NewsHikma Pharmaceuticals Plc Final ResultsLSE:HIKHikma Pharmaceuticals Plc
 Showing the most relevant articles for your search:LSE:HIK

Su Consulta Reciente

USOTC
FMFG
Farmers and Merchants Ba... (PK)
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados